Menu Search
Equities

Exscientia PLC

0RK:DUS

Exscientia PLC

Actions
  • Price (EUR)5.25
  • Today's Change-0.300 / -5.41%
  • Shares traded2.07k
  • 1 Year change+0.96%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

  • Revenue in USD (TTM)26.70m
  • Net income in USD-164.62m
  • Incorporated2021
  • Employees483.00
  • Location
    Exscientia PLCThe Schrodinger BuildingOxford Science ParkOXFORD OX4 4GEUnited KingdomGBR
  • Phone+44 186 581 8941
  • Websitehttps://www.exscientia.ai/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.